CG
ALXN

Cutler Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Cutler Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,000
Closed -$8K – 6705
2021
Q1 		$8K Buy
+1,000
New +$155K ﹤0.01% 4057
2020
Q4 		– Sell
-1,900
Closed -$5K – 5776
2020
Q3 		$5K Sell
1,900
-7,800
-80% -$841K ﹤0.01% 3581
2020
Q2 		$65K Buy
9,700
+6,200
+177% +$658K ﹤0.01% 1589
2020
Q1 		$2K Sell
3,500
-500
-13% -$49.1K ﹤0.01% 3611
2019
Q4 		$12K Buy
4,000
+3,000
+300% +$321K ﹤0.01% 2564
2019
Q3 		$7K Hold
1,000
– – ﹤0.01% 2877
2019
Q2 		$25K Hold
1,000
– – ﹤0.01% 2046
2019
Q1 		$31K Sell
1,000
-12,000
-92% -$1.49M ﹤0.01% 1763
2018
Q4 		$35K Sell
13,000
-4,300
-25% -$508K ﹤0.01% 1713
2018
Q3 		$249K Sell
17,300
-5,200
-23% -$652K 0.02% 739
2018
Q2 		$76K Sell
22,500
-24,500
-52% -$2.86M 0.01% 1336
2018
Q1 		$139K Buy
47,000
+12,800
+37% +$1.53M 0.01% 1005
2017
Q4 		$243K Sell
34,200
-36,700
-52% -$4.47M 0.01% 858
2017
Q3 		$1.39M Sell
70,900
-157,300
-69% -$21.4M 0.05% 268
2017
Q2 		$1.53M Buy
228,200
+81,100
+55% +$9.44M 0.06% 280
2017
Q1 		$214K Sell
147,100
-77,900
-35% -$10M 0.01% 1135
2016
Q4 		$557K Buy
225,000
+188,900
+523% +$23.1M 0.02% 642
2016
Q3 		$99K Sell
36,100
-122,500
-77% -$15.8M ﹤0.01% 1814
2016
Q2 		$166K Buy
158,600
+45,200
+40% +$6.41M 0.01% 1266
2016
Q1 		$443K Buy
113,400
+85,900
+312% +$12.6M 0.03% 578
2015
Q4 		$406K Buy
+27,500
New +$4.8M 0.02% 732

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Cutler Group's ALXN Position: Q3 2021 in Review

Cutler Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 745 shares — an estimated $136K sold.

Cutler Group first reported a position in ALXN in Q4 2015 and held it in 23 quarters. The position peaked at $10.9M in Q2 2017. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Cutler Group reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Cutler Group sold 745 Alexion Pharmaceuticals shares in Q3 2021, an estimated $136K.
  • Cutler Group first reported a position in Alexion Pharmaceuticals in Q4 2015 and held it in 23 quarters.
  • Cutler Group's Alexion Pharmaceuticals position peaked at $10.9M in Q2 2017.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Cutler Group's 13F filing for Q3 2021, filed 26 Oct 2021.